바이오의약품 시장 규모, 점유율, 동향 분석 보고서 : 분자 유형별, 질환별, 의약품 유형별, 의약품 개발 유형별, 제제별, 지역별, 부문 예측(2025-2030년)

Biopharmaceutical Market Growth & Trends:

The global biopharmaceutical market size is anticipated to reach USD 740.84 billion by 2030, growing at a CAGR of 8.87% from 2025 to 2030, according to a new report by Grand View Research, Inc. Key growth drivers include the rising prevalence of chronic diseases, increasing adoption of biologics for precision medicine, and advancements in biomanufacturing technologies. The growth is further supported by strong research and development investments, regulatory approvals for novel biologics, and expanding biosimilar adoption. The growing demand for monoclonal antibodies, cell and gene therapies, and recombinant proteins is reshaping treatment approaches across oncology, autoimmune diseases, and rare disorders.

The biopharmaceutical industry pipeline remains robust, with active research in gene therapies, RNA-based therapeutics, and bispecific antibodies targeting multiple indications. A notable breakthrough includes CRISPR-based gene editing therapies published in Nature Biotechnology in November 2024, demonstrating durable responses in sickle cell disease and beta-thalassemia patients.

In December 2024, Biogen and Samsung Bioepis secured EMA approval for their biosimilar adalimumab, expanding market competition in autoimmune disease treatment. This strategic move aligns with increasing global biosimilar adoption, addressing affordability challenges and improving access to high-quality biologics. With biosimilar penetration increasing across Europe and Asia, companies are leveraging cost-effective production strategies to enhance global market presence.

Additionally, the launch of subcutaneous biologics is transforming patient treatment experiences, offering convenient administration and reducing dependency on infusion centers. AbbVie's subcutaneous formulation of infliximab, approved in February 2025, is expected to capture significant market share, improving adherence and patient satisfaction.

As part of industry advancements, Lonza participated as a Platinum Sponsor at the 2024 Biologics Manufacturing Conference held in Singapore from November 20-22, focusing on innovations in large-scale biologics production. The event highlighted biopharma manufacturing trends, including single-use bioreactors, process intensification, and AI-driven biologics development, shaping the next generation of high-efficacy therapies.

These strategic initiatives underscore the growing emphasis on biopharmaceutical innovation, market expansion, and regulatory advancements aimed at improving patient outcomes worldwide.

Biopharmaceutical Market Report Highlights:

• Based on molecule type, monoclonal antibodies dominated the market in 2024, accounting for 61.05% of the total revenue due to their high specificity, broad therapeutic applications, and growing demand in oncology and autoimmune disorders. The hormone segment is projected to grow at a robust CAGR over the forecast period, driven by increasing adoption in endocrinology and metabolic disease treatments.
• Based on disease, oncology led the market with the largest revenue share in 2024, accounting for 31.00% of the total market due to the rising prevalence of cancer and increasing approvals of biologic therapies. However, the immunology segment is expected to grow at the fastest rate over the forecast period.
• Based on drug type, proprietary (branded) biopharmaceuticals held the largest revenue share in 2024, comprising 77.86% of the total market, attributed to continuous R&D investments and strong patent protection. However, biosimilars are expected to witness the fastest CAGR over the forecast period due to regulatory approvals and increasing cost-saving initiatives.
• Based on drug development type, outsourced biopharmaceutical development dominated the market in 2024, accounting for 56.15% of the total revenue as companies increasingly leverage contract development and manufacturing organizations (CDMOs) to optimize costs and accelerate commercialization.
• Based on formulation, injectable biologics (IV, IM, SC) held the largest revenue share in 2024, comprising 92.55% of the market, driven by their systemic absorption and effectiveness. However, inhalation and nasal biologics are expected to witness significant growth due to advancements in non-invasive drug delivery.
• Based on route of administration, parenteral administration (IV, IM, SC) led the market in 2024, with an 88.74% share, as most biologics require systemic delivery. Inhalation and nasal routes are expected to gain traction over the forecast period.
• Based on prescription type, prescription medicines dominated the market in 2024, accounting for 96.90% of the total revenue due to stringent regulatory oversight and the complexity of biologic therapies.
• Based on sales channel, non-retail channels, including hospitals and specialty clinics, emerged as the dominant distribution channel in 2024, accounting for 55.70% of total revenue, reflecting the need for controlled administration and storage of biologics.
• Key players operating in the biopharmaceutical industry include Amgen Inc.; Pfizer Inc.; Novartis AG; Sanofi; Merck & Co.; Roche Holding AG; Biogen Inc.; AstraZeneca; Eli Lilly and Company; and Bayer AG.
• In June 2024, Regeneron Pharmaceuticals, Inc. announced the approval of Kevzara (sarilumab) by the U.S. FDA for the treatment of active Polyarticular Juvenile Idiopathic Arthritis (pJIA) in patients 2 years and older. This approval provides a new treatment option for children affected by this chronic inflammatory condition.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Molecule Type
  • 1.2.2. Disease
  • 1.2.3. Drug Type
  • 1.2.4. Drug Development Type
  • 1.2.5. Formulation
  • 1.2.6. Route of Administration
  • 1.2.7. Prescription Type
  • 1.2.8. Sales Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Biopharmaceutical Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Pricing Analysis

Chapter 4. Biopharmaceutical Market: Molecule Type Business Analysis

• 4.1. Molecule Type Market Share, 2024 & 2030
• 4.2. Molecule Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Molecule Type , 2018 to 2030 (USD Million)
• 4.4. Monoclonal Antibody
  • 4.4.1. Monoclonal Antibody Market, 2018 - 2030 (USD Million)
• 4.5. Interferon
  • 4.5.1. Interferon Market, 2018 - 2030 (USD Million)
• 4.6. Insulin
  • 4.6.1. Insulin Market, 2018 - 2030 (USD Million)
• 4.7. Growth and Coagulation Factor
  • 4.7.1. Growth and Coagulation Factor Market, 2018 - 2030 (USD Million)
• 4.8. Erythropoietin
  • 4.8.1. Erythropoietin Market, 2018 - 2030 (USD Million)
• 4.9. Vaccine
  • 4.9.1. Vaccine Market, 2018 - 2030 (USD Million)
• 4.10. Hormone
  • 4.10.1. Hormone Market, 2018 - 2030 (USD Million)
• 4.11. Others
  • 4.11.1. Other Type Market, 2018 - 2030 (USD Million)

Chapter 5. Biopharmaceutical Market: Disease Business Analysis

• 5.1. Disease Market Share, 2024 & 2030
• 5.2. Disease Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Disease, 2018 to 2030 (USD Million)
• 5.4. Oncology
  • 5.4.1. Oncology Market, 2018 - 2030 (USD Million)
• 5.5. Blood Disorder
  • 5.5.1. Blood Disorder Market, 2018 - 2030 (USD Million)
• 5.6. Metabolic Disease
  • 5.6.1. Metabolic Disease Market, 2018 - 2030 (USD Million)
• 5.7. Infectious Disease
  • 5.7.1. Infectious Disease Market, 2018 - 2030 (USD Million)
• 5.8. Cardiovascular Disease
  • 5.8.1. Cardiovascular Disease Market, 2018 - 2030 (USD Million)
• 5.9. Neurological Disease
  • 5.9.1. Neurological Disease Market, 2018 - 2030 (USD Million)
• 5.10. Immunology
  • 5.10.1. Immunology Market, 2018 - 2030 (USD Million)
• 5.11. Others
  • 5.11.1. Other Type Market, 2018 - 2030 (USD Million)

Chapter 6. Biopharmaceutical Market: Drug Type Business Analysis

• 6.1. Drug Type Market Share, 2024 & 2030
• 6.2. Drug Type Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
• 6.4. Proprietary (Branded)
  • 6.4.1. Proprietary (Branded) Market, 2018 - 2030 (USD Million)
  • 6.4.2. Biosimilars
    • 6.4.2.1. Biosimilars Market, 2018 - 2030 (USD Million)

Chapter 7. Biopharmaceutical Market: Drug Development Type Business Analysis

• 7.1. Drug Development Type Market Share, 2024 & 2030
• 7.2. Drug Development Type Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Drug Development Type, 2018 to 2030 (USD Million)
• 7.4. Outsource
  • 7.4.1. Outsource Market, 2018 - 2030 (USD Million)
• 7.5. In-house
  • 7.5.1. In-house Market, 2018 - 2030 (USD Million)

Chapter 8. Biopharmaceutical Market: Formulation Business Analysis

• 8.1. Formulation Market Share, 2024 & 2030
• 8.2. Formulation Segment Dashboard
• 8.3. Market Size & Forecasts and Trend Analysis, by Formulation, 2018 to 2030 (USD Million)
• 8.4. Injectables (IV, IM, SC)
  • 8.4.1. Injectables (IV, IM, SC) Market, 2018 - 2030 (USD Million)
• 8.5. Inhalation/Nasal Sprays
  • 8.5.1. Inhalation/Nasal Sprays Market, 2018 - 2030 (USD Million)
• 8.6. Other Formulations
  • 8.6.1. Other Formulations Market, 2018 - 2030 (USD Million)

Chapter 9. Biopharmaceutical Market: Route of Administration Business Analysis

• 9.1. Route of Administration Market Share, 2024 & 2030
• 9.2. Route of Administration Segment Dashboard
• 9.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
• 9.4. Parenteral (IV, IM, SC)
  • 9.4.1. Parenteral (IV, IM, SC) Market, 2018 - 2030 (USD Million)
• 9.5. Inhalation/Nasal
  • 9.5.1. Inhalation/Nasal Market, 2018 - 2030 (USD Million)
• 9.6. Other Routes
  • 9.6.1. Other Routes Market, 2018 - 2030 (USD Million)

Chapter 10. Biopharmaceutical Market: Prescription Type Business Analysis

• 10.1. Prescription Type Market Share, 2024 & 2030
• 10.2. Prescription Type Segment Dashboard
• 10.3. Market Size & Forecasts and Trend Analysis, by Prescription Type, 2018 to 2030 (USD Million)
• 10.4. Prescription Medicines
  • 10.4.1. Prescription Medicines Market, 2018 - 2030 (USD Million)
• 10.5. Over-the-counter (OTC) Medicines
  • 10.5.1. Over-the-counter (OTC) Medicines Market, 2018 - 2030 (USD Million)

Chapter 11. Biopharmaceutical Market: Sales Channel Business Analysis

• 11.1. Sales Channel Market Share, 2024 & 2030
• 11.2. Sales Channel Segment Dashboard
• 11.3. Market Size & Forecasts and Trend Analysis, by Sales Channel, 2018 to 2030 (USD Million)
• 11.4. Retail Pharmacies
  • 11.4.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
• 11.5. Non-retail
  • 11.5.1. Non-retail Market, 2018 - 2030 (USD Million)

Chapter 12. Biopharmaceutical Market: Regional Estimates & Trend Analysis

• 12.1. Regional Market Share Analysis, 2024 & 2030
• 12.2. Regional Market Dashboard
• 12.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 12.4. North America
  • 12.4.1. North America Biopharmaceutical Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 12.4.2. U.S.
    • 12.4.2.1. Key Country Dynamics
    • 12.4.2.2. Target Disease Prevalence
    • 12.4.2.3. Regulatory Framework
    • 12.4.2.4. Reimbursement Framework
    • 12.4.2.5. U.S. Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.4.3. Canada
    • 12.4.3.1. Key Country Dynamics
    • 12.4.3.2. Target Disease Prevalence
    • 12.4.3.3. Regulatory Framework
    • 12.4.3.4. Reimbursement Framework
    • 12.4.3.5. U.S. Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.4.4. Mexico
    • 12.4.4.1. Key Country Dynamics
    • 12.4.4.2. Target Disease Prevalence
    • 12.4.4.3. Regulatory Framework
    • 12.4.4.4. Reimbursement Framework
    • 12.4.4.5. Mexico Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 12.5. Europe
  • 12.5.1. Europe Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.5.2. UK
    • 12.5.2.1. Key Country Dynamics
    • 12.5.2.2. Target Disease Prevalence
    • 12.5.2.3. Regulatory Framework
    • 12.5.2.4. Reimbursement Framework
    • 12.5.2.5. Uk Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.5.3. Germany
    • 12.5.3.1. Key Country Dynamics
    • 12.5.3.2. Target Disease Prevalence
    • 12.5.3.3. Regulatory Framework
    • 12.5.3.4. Reimbursement Framework
    • 12.5.3.5. Germany Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.5.4. France
    • 12.5.4.1. Key Country Dynamics
    • 12.5.4.2. Target Disease Prevalence
    • 12.5.4.3. Regulatory Framework
    • 12.5.4.4. Reimbursement Framework
    • 12.5.4.5. France Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.5.5. Italy
    • 12.5.5.1. Key Country Dynamics
    • 12.5.5.2. Target Disease Prevalence
    • 12.5.5.3. Regulatory Framework
    • 12.5.5.4. Reimbursement Framework
    • 12.5.5.5. Italy Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.5.6. Spain
    • 12.5.6.1. Key Country Dynamics
    • 12.5.6.2. Target Disease Prevalence
    • 12.5.6.3. Regulatory Framework
    • 12.5.6.4. Reimbursement Framework
    • 12.5.6.5. Spain Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.5.7. Denmark
    • 12.5.7.1. Key Country Dynamics
    • 12.5.7.2. Target Disease Prevalence
    • 12.5.7.3. Regulatory Framework
    • 12.5.7.4. Reimbursement Framework
    • 12.5.7.5. Denmark Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.5.8. Sweden
    • 12.5.8.1. Key Country Dynamics
    • 12.5.8.2. Target Disease Prevalence
    • 12.5.8.3. Regulatory Framework
    • 12.5.8.4. Reimbursement Framework
    • 12.5.8.5. Sweden Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.5.9. Norway
    • 12.5.9.1. Key Country Dynamics
    • 12.5.9.2. Target Disease Prevalence
    • 12.5.9.3. Regulatory Framework
    • 12.5.9.4. Reimbursement Framework
    • 12.5.9.5. Norway Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 12.6. Asia Pacific
  • 12.6.1. Asia Pacific Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.6.2. Japan
    • 12.6.2.1. Key Country Dynamics
    • 12.6.2.2. Target Disease Prevalence
    • 12.6.2.3. Regulatory Framework
    • 12.6.2.4. Reimbursement Framework
    • 12.6.2.5. Japan Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.6.3. China
    • 12.6.3.1. Key Country Dynamics
    • 12.6.3.2. Target Disease Prevalence
    • 12.6.3.3. Regulatory Framework
    • 12.6.3.4. Reimbursement Framework
    • 12.6.3.5. China Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.6.4. India
    • 12.6.4.1. Key Country Dynamics
    • 12.6.4.2. Target Disease Prevalence
    • 12.6.4.3. Regulatory Framework
    • 12.6.4.4. Reimbursement Framework
    • 12.6.4.5. India Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.6.5. Australia
    • 12.6.5.1. Key Country Dynamics
    • 12.6.5.2. Target Disease Prevalence
    • 12.6.5.3. Regulatory Framework
    • 12.6.5.4. Reimbursement Framework
    • 12.6.5.5. Australia Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.6.6. South Korea
    • 12.6.6.1. Key Country Dynamics
    • 12.6.6.2. Target Disease Prevalence
    • 12.6.6.3. Regulatory Framework
    • 12.6.6.4. Reimbursement Framework
    • 12.6.6.5. South Korea Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.6.7. Thailand
    • 12.6.7.1. Key Country Dynamics
    • 12.6.7.2. Target Disease Prevalence
    • 12.6.7.3. Regulatory Framework
    • 12.6.7.4. Reimbursement Framework
    • 12.6.7.5. Thailand Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 12.7. Latin America
  • 12.7.1. Latin America Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.7.2. Brazil
    • 12.7.2.1. Key Country Dynamics
    • 12.7.2.2. Target Disease Prevalence
    • 12.7.2.3. Regulatory Framework
    • 12.7.2.4. Reimbursement Framework
    • 12.7.2.5. Japan Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.7.3. Argentina
    • 12.7.3.1. Key Country Dynamics
    • 12.7.3.2. Target Disease Prevalence
    • 12.7.3.3. Regulatory Framework
    • 12.7.3.4. Reimbursement Framework
    • 12.7.3.5. China Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 12.8. Middle East and Africa
  • 12.8.1. Middle East and Africa Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.8.2. South Africa
    • 12.8.2.1. Key Country Dynamics
    • 12.8.2.2. Target Disease Prevalence
    • 12.8.2.3. Regulatory Framework
    • 12.8.2.4. Reimbursement Framework
    • 12.8.2.5. South Africa Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.8.3. Saudi Arabia
    • 12.8.3.1. Key Country Dynamics
    • 12.8.3.2. Target Disease Prevalence
    • 12.8.3.3. Regulatory Framework
    • 12.8.3.4. Reimbursement Framework
    • 12.8.3.5. Saudi Arabia Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.8.4. UAE
    • 12.8.4.1. Key Country Dynamics
    • 12.8.4.2. Target Disease Prevalence
    • 12.8.4.3. Regulatory Framework
    • 12.8.4.4. Reimbursement Framework
    • 12.8.4.5. UAE Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.8.5. Kuwait
    • 12.8.5.1. Key Country Dynamics
    • 12.8.5.2. Target Disease Prevalence
    • 12.8.5.3. Regulatory Framework
    • 12.8.5.4. Reimbursement Framework
    • 12.8.5.5. Kuwait Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 13. Competitive Landscape

• 13.1. Participant Overview
• 13.2. Company Market Position Analysis
• 13.3. Company Categorization
• 13.4. Strategy Mapping
• 13.5. Company Profiles/Listing
  • 13.5.1. F. Hoffmann-La Roche Ltd
    • 13.5.1.1. Overview
    • 13.5.1.2. Financial Performance
    • 13.5.1.3. Product Benchmarking
    • 13.5.1.4. Strategic Initiatives
  • 13.5.2. Novartis AG
    • 13.5.2.1. Overview
    • 13.5.2.2. Financial Performance
    • 13.5.2.3. Product Benchmarking
    • 13.5.2.4. Strategic Initiatives
  • 13.5.3. AbbVie Inc.
    • 13.5.3.1. Overview
    • 13.5.3.2. Financial Performance
    • 13.5.3.3. Product Benchmarking
    • 13.5.3.4. Strategic Initiatives
  • 13.5.4. Johnson & Johnson Services, Inc.
    • 13.5.4.1. Overview
    • 13.5.4.2. Financial Performance
    • 13.5.4.3. Product Benchmarking
    • 13.5.4.4. Strategic Initiatives
  • 13.5.5. Merck & Co., Inc.
    • 13.5.5.1. Overview
    • 13.5.5.2. Financial Performance
    • 13.5.5.3. Product Benchmarking
    • 13.5.5.4. Strategic Initiatives
  • 13.5.6. Pfizer Inc.
    • 13.5.6.1. Overview
    • 13.5.6.2. Financial Performance
    • 13.5.6.3. Product Benchmarking
    • 13.5.6.4. Strategic Initiatives
  • 13.5.7. Bristol-Myers Squibb Company
    • 13.5.7.1. Overview
    • 13.5.7.2. Financial Performance
    • 13.5.7.3. Product Benchmarking
    • 13.5.7.4. Strategic Initiatives
  • 13.5.8. Sanofi
    • 13.5.8.1. Overview
    • 13.5.8.2. Financial Performance
    • 13.5.8.3. Product Benchmarking
    • 13.5.8.4. Strategic Initiatives
  • 13.5.9. GSK plc.
    • 13.5.9.1. Overview
    • 13.5.9.2. Financial Performance
    • 13.5.9.3. Product Benchmarking
    • 13.5.9.4. Strategic Initiatives
  • 13.5.10. AstraZeneca
    • 13.5.10.1. Overview
    • 13.5.10.2. Financial Performance
    • 13.5.10.3. Product Benchmarking
    • 13.5.10.4. Strategic Initiatives
  • 13.5.11. Takeda Pharmaceutical Company Limited
    • 13.5.11.1. Overview
    • 13.5.11.2. Financial Performance
    • 13.5.11.3. Product Benchmarking
    • 13.5.11.4. Strategic Initiatives
  • 13.5.12. Biogen
    • 13.5.12.1. Overview
    • 13.5.12.2. Financial Performance
    • 13.5.12.3. Product Benchmarking
    • 13.5.12.4. Strategic Initiatives
  • 13.5.13. Eli Lilly and Company
    • 13.5.13.1. Overview
    • 13.5.13.2. Financial Performance
    • 13.5.13.3. Product Benchmarking
    • 13.5.13.4. Strategic Initiatives
  • 13.5.14. Novo Nordisk A/S
    • 13.5.14.1. Overview
    • 13.5.14.2. Financial Performance
    • 13.5.14.3. Product Benchmarking
    • 13.5.14.4. Strategic Initiatives
  • 13.5.15. Amgen Inc.
    • 13.5.15.1. Overview
    • 13.5.15.2. Financial Performance
    • 13.5.15.3. Product Benchmarking
    • 13.5.15.4. Strategic Initiatives